Veru: Positive Update on COVID-19 Program

 In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome (ARDS) in H1N1 influenza pulmonary inflammation murine ARDS model

Positive Phase 3 COVID-19 clinical study and preclinical influenza study further support the potential use of sabizabulin as a broad antiviral and anti-inflammatory agent for viral-induced ARDS

• Expedited meeting granted by U.S. FDA in April 2023 for Phase 3 confirmatory study in hospitalized COVID-19 patients at high risk for ARDS

• Veru plans Phase 3 clinical study in hospitalized influenza patients at high risk for ARDS

https://finance.yahoo.com/news/veru-announces-preclinical-results-expanded-123000808.html